Paper Details

  1. Home
  2. Paper Details

Beta- and gamma-interferon in chronic active hepatitis B. A pilot trial of short-term combination therapy.

Author: CaselmannW H, EisenburgJ, HofschneiderP H, KoshyR

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the effectiveness of a combination of beta- and gamma-interferon in treating 20 patients with chronic hepatitis B. The combination therapy was successful in 5 out of 10 patients, with 2 achieving complete clearance of the virus. The treatment was more effective in patients who had been infected for a shorter period (5 out of 6 responders). The study suggests that a combination of beta- and gamma-interferon may be a promising treatment option for chronic hepatitis B, especially when started early after infection.
Paper Details　
Original Abstract of the Article :
A controlled, randomized trial of a short-term, medium-dose combination therapy of beta- and gamma-interferon was performed in 20 patients with chronic active hepatitis B. According to clinical, biochemical, and histologic findings that were followed up for 16-24 mo, the combined treatment was succe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0016-5085(89)91570-9

データ提供：米国国立医学図書館（NLM）

Beta- and Gamma-Interferon: A New Approach to Chronic Active Hepatitis B

Chronic active hepatitis B, a liver infection that can cause serious complications, can be like a persistent desert storm, threatening the health and well-being of those affected. This study explored the potential of combining beta- and gamma-interferon, two types of immune-boosting proteins, as a short-term therapy for this condition. It's like bringing a caravan of different resources to combat a raging sandstorm.

Promising Results for Short-Term Combination Therapy

The study found that the combination therapy was successful in 5 out of 10 patients, with two patients achieving complete viral elimination. This is like finding a way to calm the storm and restore peace to the desert landscape. The authors also observed that the treatment was more effective in patients who were infected within the first four years, highlighting the importance of early intervention. This is like recognizing the early signs of a sandstorm and taking action to prepare for its arrival.

A New Hope for Chronic Active Hepatitis B

This study offers a glimmer of hope for those affected by chronic active hepatitis B. The combination therapy of beta- and gamma-interferon shows promise as a potential treatment option, particularly when initiated early in the course of the disease. It's like finding a new way to navigate the desert, leading to a more manageable and hopeful journey.

Dr.Camel's Conclusion

This research is a testament to the ongoing search for better treatments for chronic liver diseases. By exploring new combinations of therapies and understanding the importance of early intervention, scientists are making progress in improving the lives of patients. It's a continuous journey of discovery and innovation, like a caravan traversing a vast and challenging desert landscape.

Date :
  1. Date Completed 1989-02-22
  2. Date Revised 2019-07-07
Further Info :

Pubmed ID

2492011

DOI: Digital Object Identifier

10.1016/0016-5085(89)91570-9

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.